Healthcare Finance News January 5, 2023
Jeff Lagasse

CMS concurs with OIG’s recommendation and says it will determine whether additional guidance would help ensure more accurate ASP calculations.

In the midst of physician concerns that Part B drug reimbursements are too low, the Department of Health and Human Services’ Office of Inspector General (OIG) is suggesting the Centers for Medicare and Medicaid Services guide drugmakers in calculating the best prices for those drugs.

In a recent report the OIG reviewed the accuracy of manufacturer-reported average sales price (ASP) data. Ensuring the accuracy of ASPs is vital, said OIG, because CMS uses these prices to directly calculate payment amounts under Medicare Part B.

Comparisons of ASPs to other benchmark prices provided little insight into potential inaccuracies, the OIG said....

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, CMS, Govt Agencies, Insurance, Medicare Advantage, OIG, Pharma, Pharma / Biotech, Survey / Study, Trends
Enrollment Growth in the ACA Marketplaces
Podcast: Meena Seshamani on the Journey from CMS to Maryland's Department of Health
In search of a long-term approach to telehealth and hospital-at-home
Senate report scrutinizes Medicare Advantage marketing spend, broker practices
Trump administration to shut down CMS, HHS minority health offices amid restructuring

Share This Article